Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MLH1 negative Dostarlimab-gxly extrahepatic bile duct carcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly extrahepatic bile duct carcinoma sensitive detail...
MSH6 negative Pembrolizumab extrahepatic bile duct carcinoma sensitive detail...
MLH1 negative Pembrolizumab extrahepatic bile duct carcinoma sensitive detail...
RET fusion Pralsetinib extrahepatic bile duct carcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib extrahepatic bile duct carcinoma sensitive detail...
RET fusion Selpercatinib extrahepatic bile duct carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT04203160 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Completed USA 0
NCT04907851 Phase II Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) Completed GBR | AUS 0
NCT05239169 Phase II Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Active, not recruiting DEU 0
NCT05564403 Phase II Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT06274879 Phase II Cisplatin + Durvalumab + Gemcitabine Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer (Ablatio) Not yet recruiting CHE 0
NCT06546969 Phase I Cisplatin + Durvalumab + Gemcitabine Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer Recruiting USA 0